

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.



Hospital Corporation of China Limited

弘和仁愛醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3869)

**COMPLETION OF ISSUE OF CONVERTIBLE BONDS
UNDER SPECIFIC MANDATE**

Reference is made to the announcements of Hospital Corporation of China Limited (the “**Company**”) dated December 21, 2018, January 16, 2019 and February 1, 2019, as well as the circular of the Company dated January 16, 2019 (the “**Circular**”), in relation to, among others, the proposed issue of the Convertible Bonds to the Subscriber under a specific mandate. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as ascribed to them in the Circular.

The Board is pleased to announce that all conditions precedent of the Amended Subscription Agreement have been fulfilled and Closing took place on February 27, 2019. Upon Closing and pursuant to the Amended Subscription Agreement, the Company has issued to the Subscriber and the Subscriber has subscribed for the Convertible Bonds in an aggregate principal amount of HK\$800,000,000 with an initial conversion price of HK\$20.00 per Conversion Share.

By order of the Board
Hospital Corporation of China Limited
Zhao John Huan
Chairman

Beijing, China, February 27, 2019

As at the date of this announcement, the directors of the Company are Mr. LU Wenzuo being the executive Director; Mr. ZHAO John Huan, Mr. LIN Sheng, Ms. LIU Lu and Ms. WANG Nan being the non-executive Directors; Ms. CHEN Xiaohong, Mr. SHI Luwen and Mr. ZHOU Xiangliang being the independent non-executive Directors.